Takeda Pharmaceutical Company Limited
【Takeda Pharmaceutical】Juliet Kim Appointed as President and CEO ｜ June 2026
Takeda Pharmaceutical has appointed Juliet Kim as President and CEO, planning three new product launches and five late-stage development projects within the next 12 months.
Key Figures
- Number of new product launches planned: 3 (by 2026)
- Late-stage development projects: 5 (in progress)
- Board composition: 11 members (including 8 outside directors)
AI要約
Overview of Executive Personnel Changes and Corporate Strategy
Takeda Pharmaceutical announced that following its 150th Annual General Meeting of Shareholders held on June 24, 2026, Juliet Kim officially assumed the position of President and CEO. Ms. Kim brings over 30 years of experience in global healthcare, and will lead the advancement of new business initiatives and product launches. Under the new board structure, the company aims to create value for patients and stakeholders, with plans to launch three key new products and advance five late-stage development projects.
Board of Directors and Future Direction of the Company
The newly appointed directors include experienced executives following the Shire acquisition and outside directors with a global perspective. The board consists of 11 members, including 8 outside directors. This composition ensures transparency and objectivity, while focusing on long-term shareholder value enhancement and innovation promotion. Ms. Kim will prioritize patient-centric R&D and the creation of innovative pharmaceuticals to achieve sustainable growth.
Takeda Pharmaceutical Company Limited
Company overview · Stock price · Financial data · All IR
